Ruixin Intelligent Medical Technology

Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. (Raysightmed) is a medical technology company founded in December 2017. Headquartered in Shenzhen, China, the company specializes in developing intelligent diagnosis and treatment solutions for cardiovascular, cerebrovascular, and peripheral vascular diseases. Raysightmed operates on a B2B model, providing its technology to hospitals and clinical partners. The company's product portfolio includes RuiXin-FFR, a non-invasive diagnostic system for assessing coronary artery blood flow (NMPA and CE certified), RuiXin-CoronaryAI for intelligent CT image processing, AngioQFA for intraoperative functional assessment, and RuiXin-Planner for preoperative surgical planning. A significant innovation is their fully automatic AI vascular interventional surgical robot, which allows doctors to issue natural language commands for automated surgical operations, aiming to automate repetitive procedures and assist in complex surgeries. Raysightmed has raised $7.02 million over three funding rounds, with investors including Matrix Partners China, China Growth Capital, and Tencent. The company has collaborated with over 800 hospitals, holds more than 200 patents, and its products have been used in over 200,000 cases.